Form of Aplindore CVR Agreement CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • August 24th, 2009 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [ — ], 2009 (this “Agreement”, is entered into by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Buyer”), Neurogen Corporation, a Delaware corporation (“Target”), and [ — ], a [ — ], as Rights Agent (the “Rights Agent”) and as initial Aplindore CVR Registrar (as defined herein).
Form of H3 CVR Agreement CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • August 24th, 2009 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [ — ], 2009 (this “Agreement”, is entered into by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Buyer”), Neurogen Corporation, a Delaware corporation (“Target”), and [ — ], a [ — ], as Rights Agent (the “Rights Agent”) and as initial H3 CVR Registrar (as defined herein).
VOTING AGREEMENTVoting Agreement • August 24th, 2009 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This VOTING AGREEMENT (this “Agreement”), is made and entered into on and as of August , 2009, by and between Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Parent”), and the undersigned stockholder (“Stockholder”) of Neurogen Corporation, a Delaware corporation (the “Company”).
Form of Real Estate CVR Agreement CONTINGENT VALUE RIGHTS AGREEMENTValue Rights Agreement • August 24th, 2009 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of [ — ], 2009 (this “Agreement”, is entered into by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation (“Buyer”), Neurogen Corporation, a Delaware corporation (“Target”), and [ — ], a [ — ], as Rights Agent (the “Rights Agent”) and as initial Real Estate CVR Registrar (as defined herein).
